Prothena Corp Public (PRTA) Non-Current Deffered Revenue (2012 - 2025)
Prothena Corp Public (PRTA) recorded quarterly Non-Current Deffered Revenue of $1.6 million in Q1 2025, down 53.6% quarter-over-quarter from $3.4 million in Q4 2024, and down 97.63% on a YoY basis from $67.4 million in Q1 2024.
Prothena Corp Public (PRTA) Non-Current Deffered Revenue (2012 - 2025) Analysis & Trends
Prothena Corp Public's Non-Current Deffered Revenue history runs 14 years deep, the most recent figure standing at $1.6 million for Q1 2025.
- In Q1 2025, Non-Current Deffered Revenue fell 97.63% year-over-year to $1.6 million; the TTM figure through Mar 2025 stood at $1.6 million (down 97.63% YoY), while the FY2024 annual figure was $3.4 million, down 94.88% from the prior year.
- Non-Current Deffered Revenue was $1.6 million for Q1 2025 at Prothena Corp Public, down from $3.4 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $110.2 million in Q1 2021 to a low of $1.6 million in Q1 2025.
- Historically, Non-Current Deffered Revenue has averaged $68.1 million across 5 years, with a median of $85.3 million in 2021.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue advanced 15.31% in 2022, then plunged 97.63% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $102.9 million in 2021, then slipped by 17.14% to $85.3 million in 2022, then retreated by 20.97% to $67.4 million in 2023, then plunged by 94.88% to $3.4 million in 2024, then sank by 53.6% to $1.6 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $1.6 million (Q1 2025), $3.4 million (Q4 2024), and $5.6 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 7.37 Mn |
| Mar 31, 2024 | 67.41 Mn |
| Dec 31, 2023 | 67.41 Mn |
| Sep 30, 2023 | 67.41 Mn |
| Jun 30, 2023 | 67.41 Mn |
| Mar 31, 2023 | 85.29 Mn |
| Dec 31, 2022 | 85.29 Mn |
| Sep 30, 2022 | 96.99 Mn |
| Jun 30, 2022 | 98.35 Mn |
| Mar 31, 2022 | 100.64 Mn |
| Dec 31, 2021 | 102.93 Mn |
| Sep 30, 2021 | 104.56 Mn |
| Jun 30, 2021 | 85.29 Mn |
| Mar 31, 2021 | 110.24 Mn |
| Dec 31, 2020 | 110.24 Mn |
| Sep 30, 2020 | 110.24 Mn |
| Jun 30, 2020 | 110.24 Mn |